Form 4: Bristol Myers Squibb EVP Reports Stock Transactions
Insider Transaction Report
Bristol Myers Squibb's EVP of Corporate Affairs, Wendy Short Bartie, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.
Summary
- Wendy Short Bartie, Executive Vice President of Corporate Affairs at Bristol Myers Squibb Co (BMY), reported stock transactions on August 2, 2025.
- Acquired 738 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
- Disposed of 378 shares of Common Stock at $44.23 per share. This sale was specifically for the payment of taxes upon the vesting of the award.
- Following these transactions, beneficial ownership of Common Stock decreased from 5,444 shares to 5,066 shares.
Sentiment
Score: 5
Explanation: The filing reports routine executive compensation events, including the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities, which is a neutral event for the company's operational performance.
Positives
- The vesting of 738 Restricted Stock Units indicates the fulfillment of executive compensation, aligning management's interests with shareholder value creation over time.
Negatives
- The disposition of 378 shares, even for tax purposes, results in a slight reduction in the direct beneficial ownership of Common Stock by a key executive.
Risks
- No specific new risks are identified or discussed within this Form 4 filing. The transactions are routine compensation-related events.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.
Industry Context
This filing details a routine executive compensation event, which is common across the pharmaceutical and broader corporate sectors. It does not provide information on broader industry trends or competitive dynamics.
Stakeholder Impact
- Shareholders: A minor, routine adjustment to insider ownership due to compensation vesting and tax withholding, with minimal direct impact on overall share value or company operations.
Key Dates
| Date | Description |
|---|---|
| 08/02/2022 | Start date for the vesting schedule of the Restricted Stock Units, with vesting occurring in four equal installments. |
| 08/02/2025 | Date of the reported transactions, including the vesting of Restricted Stock Units and the subsequent sale of shares for tax purposes. |
| 08/05/2025 | Date the Form 4 was signed by the attorney-in-fact for Wendy Short Bartie. |
Recommendation
holdThe filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. This type of transaction is common and does not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation.
Keywords
Bristol Myers Squibb, BMY, Form 4, Insider Trading, Stock Vesting, Executive Compensation, Pharmaceutical, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.